Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

Cited In for PubMed (Select 17043737)

2.

Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.

Heijmen L, Ter Voert EE, Oyen WJ, Punt CJ, van Spronsen DJ, Heerschap A, de Geus-Oei LF, van Laarhoven HW.

PLoS One. 2015 Apr 1;10(4):e0120823. doi: 10.1371/journal.pone.0120823. eCollection 2015.

3.

Multimodality functional imaging in radiation therapy planning: relationships between dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET.

Mera Iglesias M, Aramburu Núñez D, Del Olmo Claudio JL, López Medina A, Landesa-Vázquez I, Salvador Gómez F, Driscoll B, Coolens C, Alba Castro JL, Muñoz V.

Comput Math Methods Med. 2015;2015:103843. doi: 10.1155/2015/103843. Epub 2015 Feb 19.

4.

Hypoxia in head and neck cancer in theory and practice: a PET-based imaging approach.

Marcu LG, Harriss-Phillips WM, Filip SM.

Comput Math Methods Med. 2014;2014:624642. doi: 10.1155/2014/624642. Epub 2014 Aug 21. Review.

5.

Redox- and hypoxia-responsive MRI contrast agents.

Do QN, Ratnakar JS, Kovács Z, Sherry AD.

ChemMedChem. 2014 Jun;9(6):1116-29. doi: 10.1002/cmdc.201402034. Epub 2014 May 13. Review.

6.

Influence of acute hypoxia and radiation quality on cell survival.

Tinganelli W, Ma NY, Von Neubeck C, Maier A, Schicker C, Kraft-Weyrather W, Durante M.

J Radiat Res. 2013 Jul;54 Suppl 1:i23-30. doi: 10.1093/jrr/rrt065.

7.

Clinically relevant modeling of tumor growth and treatment response.

Yankeelov TE, Atuegwu N, Hormuth D, Weis JA, Barnes SL, Miga MI, Rericha EC, Quaranta V.

Sci Transl Med. 2013 May 29;5(187):187ps9. doi: 10.1126/scitranslmed.3005686.

8.

Evaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.

Ballegeer EA, Madrill NJ, Berger KL, Agnew DW, McNiel EA.

BMC Cancer. 2013 Apr 30;13:218. doi: 10.1186/1471-2407-13-218.

9.

PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.

Balyasnikova S, Löfgren J, de Nijs R, Zamogilnaya Y, Højgaard L, Fischer BM.

Am J Nucl Med Mol Imaging. 2012;2(4):458-74. Epub 2012 Oct 15.

10.

In vivo visualization of heterogeneous intratumoral distribution of hypoxia-inducible factor-1α activity by the fusion of high-resolution SPECT and morphological imaging tests.

Fujii H, Yamaguchi M, Inoue K, Mutou Y, Ueda M, Saji H, Kizaka-Kondoh S, Moriyama N, Umeda IO.

J Biomed Biotechnol. 2012;2012:262741. doi: 10.1155/2012/262741. Epub 2012 Jun 12.

11.

Modelling and detecting tumour oxygenation levels.

Skeldon AC, Chaffey G, Lloyd DJ, Mohan V, Bradley DA, Nisbet A.

PLoS One. 2012;7(6):e38597. doi: 10.1371/journal.pone.0038597. Epub 2012 Jun 28.

12.

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.

Hansen AE, Kristensen AT, Jørgensen JT, McEvoy FJ, Busk M, van der Kogel AJ, Bussink J, Engelholm SA, Kjær A.

Radiat Oncol. 2012 Jun 15;7:89. doi: 10.1186/1748-717X-7-89.

13.

Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.

Jordan BF, Sonveaux P.

Front Pharmacol. 2012 May 21;3:94. doi: 10.3389/fphar.2012.00094. eCollection 2012.

14.

Imaging hypoxia in gliomas.

Mendichovszky I, Jackson A.

Br J Radiol. 2011 Dec;84 Spec No 2:S145-58. doi: 10.1259/bjr/82292521. Review.

15.

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

Tunariu N, Kaye SB, Desouza NM.

Br J Cancer. 2012 Feb 14;106(4):619-28. doi: 10.1038/bjc.2011.579. Epub 2012 Jan 26. Review.

16.

Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Maier FC, Kneilling M, Reischl G, Cay F, Bukala D, Schmid A, Judenhofer MS, Röcken M, Machulla HJ, Pichler BJ.

Radiat Oncol. 2011 Nov 25;6:165. doi: 10.1186/1748-717X-6-165.

17.

Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.

Kersemans V, Cornelissen B, Hueting R, Tredwell M, Hussien K, Allen PD, Falzone N, Hill SA, Dilworth JR, Gouverneur V, Muschel RJ, Smart SC.

PLoS One. 2011;6(11):e25911. doi: 10.1371/journal.pone.0025911. Epub 2011 Nov 15.

18.

Modulation of tumor hypoxia by topical formulations with vasodilators for enhancing therapy.

Abramovic Z, Hou H, Julijana K, Sentjurc M, Lariviere JP, Swartz HM, Khan N.

Adv Exp Med Biol. 2011;701:75-82. doi: 10.1007/978-1-4419-7756-4_11.

19.

In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors.

Busk M, Toustrup K, Sørensen BS, Alsner J, Horsman MR, Jakobsen S, Overgaard J.

BMC Cancer. 2011 Feb 9;11:63. doi: 10.1186/1471-2407-11-63.

20.

Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X.

Mol Pharm. 2011 Apr 4;8(2):621-8. doi: 10.1021/mp100446t. Epub 2011 Feb 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk